
    
      This study is intended to observe and collect data on the usage, dosing, tolerability, and
      effectiveness of lopinavir/ritonavir (Kaletra) when used as part of a Nucleoside Reverse
      Transcriptase Inhibitors-free double protease regimen. Enrollment in the study was
      independent of the decision to prescribe Kaletra.
    
  